IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v15y2024i1d10.1038_s41467-024-48278-1.html
   My bibliography  Save this article

Engineering and evaluation of FXa bypassing agents that restore hemostasis following Apixaban associated bleeding

Author

Listed:
  • Wojciech Jankowski

    (Center for Biologics Evaluation & Research, US FDA)

  • Stepan S. Surov

    (Center for Biologics Evaluation & Research, US FDA)

  • Nancy E. Hernandez

    (Center for Biologics Evaluation & Research, US FDA)

  • Atul Rawal

    (Center for Biologics Evaluation & Research, US FDA)

  • Marcos Battistel

    (Center for Biologics Evaluation & Research, US FDA)

  • Daron Freedberg

    (Center for Biologics Evaluation & Research, US FDA)

  • Mikhail V. Ovanesov

    (Center for Biologics Evaluation & Research, US FDA)

  • Zuben E. Sauna

    (Center for Biologics Evaluation & Research, US FDA)

Abstract

Direct oral anticoagulants (DOACs) targeting activated factor Xa (FXa) are used to prevent or treat thromboembolic disorders. DOACs reversibly bind to FXa and inhibit its enzymatic activity. However, DOAC treatment carries the risk of anticoagulant-associated bleeding. Currently, only one specific agent, andexanet alfa, is approved to reverse the anticoagulant effects of FXa-targeting DOACs (FXaDOACs) and control life-threatening bleeding. However, because of its mechanism of action, andexanet alfa requires a cumbersome dosing schedule, and its use is associated with the risk of thrombosis. Here, we present the computational design, engineering, and evaluation of FXa-variants that exhibit anticoagulation reversal activity in the presence of FXaDOACs. Our designs demonstrate low DOAC binding affinity, retain FXa-enzymatic activity and reduce the DOAC-associated bleeding by restoring hemostasis in mice treated with apixaban. Importantly, the FXaDOACs reversal agents we designed, unlike andexanet alfa, do not inhibit TFPI, and consequently, may have a safer thrombogenic profile.

Suggested Citation

  • Wojciech Jankowski & Stepan S. Surov & Nancy E. Hernandez & Atul Rawal & Marcos Battistel & Daron Freedberg & Mikhail V. Ovanesov & Zuben E. Sauna, 2024. "Engineering and evaluation of FXa bypassing agents that restore hemostasis following Apixaban associated bleeding," Nature Communications, Nature, vol. 15(1), pages 1-9, December.
    • Handle: RePEc:nat:natcom:v:15:y:2024:i:1:d:10.1038_s41467-024-48278-1
    DOI: 10.1038/s41467-024-48278-1
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-024-48278-1
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/s41467-024-48278-1?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Christine E. Tinberg & Sagar D. Khare & Jiayi Dou & Lindsey Doyle & Jorgen W. Nelson & Alberto Schena & Wojciech Jankowski & Charalampos G. Kalodimos & Kai Johnsson & Barry L. Stoddard & David Baker, 2013. "Computational design of ligand-binding proteins with high affinity and selectivity," Nature, Nature, vol. 501(7466), pages 212-216, September.
    2. Daniël Verhoef & Koen M. Visscher & C. Ruben Vosmeer & Ka Lei Cheung & Pieter H. Reitsma & Daan P. Geerke & Mettine H. A. Bos, 2017. "Engineered factor Xa variants retain procoagulant activity independent of direct factor Xa inhibitors," Nature Communications, Nature, vol. 8(1), pages 1-10, December.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Namrata Anand & Raphael Eguchi & Irimpan I. Mathews & Carla P. Perez & Alexander Derry & Russ B. Altman & Po-Ssu Huang, 2022. "Protein sequence design with a learned potential," Nature Communications, Nature, vol. 13(1), pages 1-11, December.
    2. Betz, Ulrich A.K. & Arora, Loukik & Assal, Reem A. & Azevedo, Hatylas & Baldwin, Jeremy & Becker, Michael S. & Bostock, Stefan & Cheng, Vinton & Egle, Tobias & Ferrari, Nicola & Schneider-Futschik, El, 2023. "Game changers in science and technology - now and beyond," Technological Forecasting and Social Change, Elsevier, vol. 193(C).

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:15:y:2024:i:1:d:10.1038_s41467-024-48278-1. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.